<DOC>
	<DOCNO>NCT01862081</DOCNO>
	<brief_summary>This open-label , multicenter , dose-escalation study design assess safety , tolerability , pharmacokinetics oral GDC-0032 administer combination either docetaxel paclitaxel . Patients treat GDC-0032 docetaxel HER2-negative locally recurrent metastatic breast cancer non-small cell lung cancer ( NSCLC ) . Patients treat GDC-0032 paclitaxel combination human epidermal growth factor receptor 2 ( HER2 ) -negative locally recurrent metastatic breast cancer . There two potential stage within arm study : dose-escalation stage ( Stage 1 ) dose-expansion stage ( Stage 2 ) . Once maximum tolerate dose GDC-0032 give arm establish dose escalation , additional patient combination enrol Stage 2 .</brief_summary>
	<brief_title>A Dose-escalation Study Assess Safety , Tolerability , Pharmacokinetics GDC-0032 Combination With Docetaxel With Paclitaxel Patients With HER2-negative Locally Recurrent Metastatic Breast Cancer Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age &gt; =18 year For paclitaxel combination arm : histologically cytologically document adenocarcinoma breast locally recurrent metastatic disease For docetaxel combination arm : histologically cytologically document adenocarcinoma breast locally recurrent metastatic disease histologically document advanced ( Stage IV ) recurrent NSCLC For participant breast cancer : HER2negative disease define local clinical guideline Participants NSCLC treat docetaxel need receive least one prior anticancer treatment regimen advance set docetaxel consider appropriate treatment Evaluable measurable disease per response evaluation criterion solid tumor ( RECIST ) v.1.1 Life expectancy &gt; =12 week Eastern cooperative oncology group ( ECOG ) performance status 0 1 screen Adequate hematologic end organ function Use highly effective form contraception Prior anticancer therapy Prior treatment phosphoinositide 3kinase ( PI3K ) inhibitor Known significant hypersensitivity component study treatment Grade &gt; =2 peripheral neuropathy Type 1 Type 2 diabetes Grade &gt; =2 hypercholesterolemia hypertriglyceridemia Congenital long QT syndrome Active congestive heart failure ventricular arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>